Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

CHEBI:60634 methyl 2-[(3S,5S)-5-[[4-[4-(N'...

Synonyms:

Akkerhuis, K.M. et al., Müller, T.H. et al., Drewe, J. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lefradafiban

We assessed the safety and preliminary efficacy of 1 month treatment with three dose levels of the oral GP IIb/IIIa blocker lefradafiban in patients with unstable angina or myocardial infarction without persistent ST elevation [1].
There was an increased incidence of neutropenia (neutrophils <1. 5 x 10(9)/l) in the lefradafiban groups (5.2% vs 1.5% in the placebo group), which did not result from bone marrow depression but rather from a reversible redistribution of neutrophils by margination or clustering [1].

High impact information on Lefradafiban

Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men [2].
Absorption of lefradafiban from different sites of the gastrointestinal tract [3].

References

Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Akkerhuis, K.M., Neuhaus, K.L., Wilcox, R.G., Vahanian, A., Boland, J.L., Hoffmann, J., Baardman, T., Nehmiz, G., Roth, U., Klootwijk, A.P., Deckers, J.W., Simoons, M.L. Eur. Heart J. (2000) [Pubmed]
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Müller, T.H., Weisenberger, H., Brickl, R., Narjes, H., Himmelsbach, F., Krause, J. Circulation (1997) [Pubmed]
Absorption of lefradafiban from different sites of the gastrointestinal tract. Drewe, J., Narjes, H., Heinzel, G., Brickl, R.S., Rohr, A., Beglinger, C. British journal of clinical pharmacology. (2000) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share